Myo-inositol may prevent gestational diabetes in PCOS women
Myo-inositol may prevent gestational diabetes in PCOS women
复制标题
DOI：
10.3109/09513590.2011.633665
复制
发表时间：
2012-06-01
影响因子：
2
通讯作者：
Di Benedetto, A.
中科院分区：
文献类型：
--
作者：
D'Anna, R.;Di Benedetto, V.;Di Benedetto, A.
回顾性评价多囊卵巢综合征妇女服用肌醇后妊娠期糖尿病（GD）的患病率。3年内，共有98例多囊卵巢综合症女性怀孕，无论是使用肌醇（n. 54），或与二甲双胍（n. 44)被考虑。虽然肌醇在整个妊娠期间都被假定，但二甲双胍治疗组的女性在妊娠诊断后停止药物假设，并被视为对照组。在排除流产和双胎妊娠的病例后，对肌醇组46名妇女和对照组37名妇女的确切人数进行了回顾性评价。主要结局指标为两组GD发生率;而次要结局指标为妊娠结局：高血压疾病、早产、巨大儿和剖腹产发生率。肌醇组GD患病率为17.4%，对照组为54%，校正协变量后差异也非常显著。因此，在对照组中，发生GD的风险是肌醇组的两倍多，比值比为2.4（置信区间95%，1.3-4.4）。两组之间在次要结局指标方面没有差异。这项研究表明肌醇在PCOS妇女GD的一级预防中可能有作用。
To evaluate retrospectively the prevalence of gestational diabetes (GD) in pregnancies obtained with myo-inositol administration in women with polycystic ovary syndrome. A total of 98 pregnancies in PCOS women obtained in a 3-year period, either with myo-inositol (n. 54), or with metformin (n. 44) were considered. While myo-inositol was assumed through the whole pregnancy, the group of women treated with metformin stopped the drug assumption after pregnancy diagnosis, and was considered as a control group. After having eliminated cases of miscarriages and twin pregnancies, a definitive number of 46 women in the myo-inositol group and 37 in the control group was taken in account to be retrospectively evaluated. The primary outcome measure was GD occurrence in both groups; whereas secondary outcome measures were pregnancy outcomes: hypertensive disorders, pre-term birth, macrosomia and caesarean section occurrence. Prevalence of GD in the myo-inositol group was 17.4% versus 54% in the control group, with a highly significant difference also after adjusting for covariates. Consequently, in the control group the risk of GD occurrence was more than double compared to the myo-inositol group, with an odds ratio 2.4 (confidence interval 95%, 1.3-4.4). There was no difference between the groups in relation to secondary outcome measures. This study suggests a possible effect of myo-inositol in the primary prevention of GD in PCOS women.